<DOC>
	<DOC>NCT00892203</DOC>
	<brief_summary>This study will assess the efficacy and safety of BGG492 used to treat migraine pain.</brief_summary>
	<brief_title>Efficacy and Safety of BGG492 in the Treatment of Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Diagnosis of moderate to severe migraine for at least 1 year At least 1 migraine episode, but not more 15 migraine days per month Past use of triptans Migraine onset before 50 years of age Diagnosis of basilar, ophthalmoplegic or hemiplegic migraine. More than 6 nonmigraine headaches per month Patients receiving migraine prophylaxis treatment Patients receiving regular treatment with psychoactive drugs Smokers Patients with a very high or low body weight Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
</DOC>